A Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO™) or Standard Care Dressings (AQUACEL® Ag SURGICAL Dressing)

A Prospective, Randomized, Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO™) or Standard Care Dressings (AQUACEL® Ag SURGICAL Dressing)

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02664168

Enrollment

Unknown

Registered

2016-01-26

Start date

2016-01-31

Completion date

Unknown

Last updated

2018-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Wound Infection

Brief summary

The aim of this study is to assess the prevention of incision healing complications in patients undergoing revision TKA and THA treated with either Single-Use NPWT (PICO) compared to standard of care dressings (AQUACEL Ag Surgical Dressing). All patients undergoing a revision TKA and THA who consent to taking part in the study, and meet the eligibility criteria will be included onto the study. Patients will be followed up for a period of up to 3 months to determine if there are any latent incision healing complications

Interventions

DEVICEAquacel Ag Surgical Dressing

DEVICESingle-Use Negative Pressure Wound Therapy (PICO)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patient ≥18 years old 2. Male or non-pregnant, non-lactating, postmenopausal or surgically sterilized females 3. Subjects undergoing revision total knee arthroplasty or revision total hip arthroplasty 4. Subjects provide informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information 5. Subjects deemed able to understand and comply with study visit schedule and procedures

Exclusion criteria

1. Wounds that require daily inspection 2. Active bleeding within the surgical site 3. Pregnant, lactating females, or females of childbearing potential not willing to practice an effective method of contraception 4. Subjects on warfarin therapy. Resulting in increased exudate and prolonging hospital stay following surgery to achieve therapeutic INR levels 5. Skin integrity issues that preclude the use of Negative Pressure Wound Therapy (NPWT) 6. Subjects undergoing primary total joint procedures 7. Subjects with a known history of poor compliance with medical treatment 8. Subjects who have participated in this trial previously and who were withdrawn 9 . Subjects with known allergies to product components (silicone adhesives and polyurethane films (direct contact with wound), acrylic adhesives (direct contact with skin), polyethylene fabrics and super-absorbent powders (polyacrylates) (within the dressing)

Design outcomes

Primary

Measure	Time frame
Incidence of Surgical Site Infection	90 days post-op

Countries

United States

Contacts

Primary ContactTiffany Morrison, MS

tiffany.morrison@rothmaninstitute.com267-339-7818

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026